The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations
Author(s): 
Pages: 794-796
Year: Issue:  10
Journal: Chinese Journal of Internal Medicine

Keyword:  Leukemiamyeloidchronic-phaseMutationABL kinase domain;
Abstract: To retrospectively analyze the efficacy of interferon plus imatinib (IM) in patients with chronic-phase chronic myelogenous leukemia (CML-CP) and ABL kinase domain mutations.The mutation rates of ABL kinase region in patients with Sokal score low,medium and high risk CML-CP were statistically significant (6.25%,9.42% and 47.06%,P <0.05).The response rates of interferon plus IM versus second-generation TKI in CML-CP with non-T315I ABL kinase domain mutations were comparable (61.11%vs 65.52%,P > 0.05).When CML-CP patients with ABL kinase domain mutations were resistant to TKI or not accessible to second-generation TKI,interferon plus IM can be an alternative choice.
Related Articles
No related articles found